E1 ReplicatedModerate confidencePEM unclearRCTPeer-reviewedMachine draft
Changes in the 2-5A synthetase/RNase L antiviral pathway in a controlled clinical trial with poly(I)-poly(C12U) in chronic fatigue syndrome.
Suhadolnik, R J, Reichenbach, N L, Hitzges, P et al. · In vivo (Athens, Greece) · 1994
Quick Summary
This study looked at whether a drug called poly(I)-poly(C12U) could help ME/CFS by measuring specific immune markers in the blood. Researchers found that people with ME/CFS had higher levels of these immune markers than healthy controls, and when treated with the drug, these markers decreased along with improvements in thinking and memory problems.
Why It Matters
This study provides molecular evidence that ME/CFS involves dysregulation of an antiviral defense pathway, potentially explaining some symptoms and offering a biological target for treatment. The correlation between biochemical improvement and cognitive recovery suggests that abnormalities in this pathway may directly contribute to patient symptoms.
Observed Findings
- Mean bioactive 2-5A and RNase L activity were significantly elevated at baseline in ME/CFS patients compared to controls (p<0.0001 and p=0.001).
- In patients with elevated baseline RNase L, poly(I)-poly(C12U) treatment significantly decreased RNase L activity (p=0.005).
- Decreased RNase L activity correlated with cognitive/neuropsychological improvement (p=0.007).
- Bioactive 2-5A also showed a trend toward decrease with treatment (p=0.09).
Inferred Conclusions
- The 2-5A/RNase L antiviral pathway is dysregulated in ME/CFS at baseline.
- Poly(I)-poly(C12U) is biologically active and can normalize aberrant 2-5A/RNase L pathway activation in some ME/CFS patients.
- Biochemical improvements in RNase L activity may be mechanistically linked to symptom improvement, particularly cognitive symptoms.
Remaining Questions
- Does normalization of RNase L activity cause cognitive improvement, or is it merely associated with recovery from a separate underlying process?
- What determines which ME/CFS patients have elevated baseline RNase L, and are these a distinct subgroup?
- What is the long-term efficacy and safety of poly(I)-poly(C12U) treatment in ME/CFS?
What This Study Does Not Prove
This study does not prove that poly(I)-poly(C12U) is an effective treatment for all ME/CFS patients, as it shows changes only in patients with elevated baseline RNase L and does not establish causation between RNase L elevation and ME/CFS symptoms. The abstract does not report overall clinical efficacy or long-term outcomes. Small patient numbers and the lack of detailed baseline characteristics limit generalizability.
Tags
Symptom:Cognitive DysfunctionFatigue
Biomarker:Blood Biomarker
Method Flag:Exploratory Only
Metadata
- PMID
- 7893988
- Review status
- Machine draft
- Evidence level
- Replicated human evidence from multiple independent studies
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →